CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.77BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.76xvs all stocks
52-Week Change
470.00%vs all stocks
Market Capitalization
8.77BUSDvs all stocks (USD)
Enterprise Value
7.98BUSDvs all stocks (USD)
Forward P/E
-32.56xvs Biotechnology peers
Price to Book (MRQ)
6.21xvs Biotechnology peers
Enterprise to EBITDA
-22.34xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-23.04%vs Biotechnology peers
Return on Equity (TTM)
-35.32%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
-284.30MUSDvs all stocks (USD)
EBITDA (TTM)
-357.20MUSDvs all stocks (USD)
Net Income (TTM)
-326.53MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-282.21MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-176.03MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-326.20MUSDvs all stocks (USD)
Pre-tax Income
-303.27MUSDFY2025 · Dec 31, 2025Net Income
-303.27MUSDFY2025 · Dec 31, 2025EBIT
-326.20MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-326.06MUSDFY2025 · Dec 31, 2025Research & Development
267.12MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
59.08MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-303.27MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-257.32MUSDFY2025 · Dec 31, 2025Free Cash Flow
-257.37MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
357.75MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-303.27MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
140.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
33.94MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.03MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
12.10MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.26MUSDFY2025 · Dec 31, 2025Capital Expenditures
-56.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-623.81MUSDFY2025 · Dec 31, 2025Sale of Investments
312.72MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-311.15MUSDFY2025 · Dec 31, 2025Other Financing Charges
-2.09MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
688.90MUSDFY2025 · Dec 31, 2025Shares Outstanding
27.86MSharesUpdated Jul 19, 2026Float Shares
24.04MSharesUpdated Jul 19, 2026Shares Short
3.99MSharesUpdated Jul 19, 2026Short Ratio
5.56daysvs all stocks
Short % of Shares Outstanding
14.34%vs all stocks
% Held by Insiders
0.28%vs all stocks
% Held by Institutions
116.76%vs all stocks
Total Cash (MRQ)
786.87MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
28.23USDUpdated Jul 19, 2026Total Debt (MRQ)
1.44MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0010xvs Biotechnology peers
Current Ratio (MRQ)
15.88xvs Biotechnology peers
Book Value per Share (MRQ)
50.61USDUpdated Jul 19, 2026Total Assets
937.91MUSDvs all stocks (USD)
Total Current Assets
610.91MUSDFY2025 · Dec 31, 2025Total Liabilities
59.77MUSDFY2025 · Dec 31, 2025Total Non-current Assets
327.00MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
0.00USDFY2025 · Dec 31, 2025Total Current Liabilities
59.77MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
357.33MUSDFY2025 · Dec 31, 2025Other Short-term Investments
242.00MUSDFY2025 · Dec 31, 2025Accounts Payable
24.63MUSDFY2025 · Dec 31, 2025Short-term Debt
110.00KUSDFY2025 · Dec 31, 2025Long-term Debt
0.00USDFY2025 · Dec 31, 2025Common Stock (Book)
15.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.14BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
878.14MUSDvs all stocks (USD)
52-Week Low
37.19USDUpdated Jul 19, 202652-Week High
366.52USDUpdated Jul 19, 202652-Week Change
470.00%vs all stocks
Beta
2.76xvs all stocks
50-Day MA
312.50USDUpdated Jul 19, 2026200-Day MA
271.59USDUpdated Jul 19, 2026Avg 10-Day Volume
378.92KSharesUpdated Jul 19, 2026Avg 30-Day Volume
577.16KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-13.39USDUpdated Jul 19, 2026Other Income / Expense
22.93MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.69
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $8.77B, above the global median of $1.15BNotable
Market cap (USD): 8,765,365,333Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Spyre Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. A Shares
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Bruker Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Alkermes plc
Tier 1ProductionApproval-Gated PipelineRule
Crinetics Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ionis Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Protagonist Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
TG Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Glaukos Corporation
Tier 1ProductionApproval-Gated PipelineRule
Halozyme Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Joinn Laboratories China Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Relay Therapeutics Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Shattuck Labs Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity